Hematologic Oncology

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

Eunice Wang, MD, discusses the utility of minimal residual disease testing in hematologic malignancies and challenges associated with expanding its role in clinical practice for acute myeloid leukemia.

Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.

A brief review of T-Cell acute lymphoblastic leukemia and emerging novel therapies that may improve upon its existent treatment armamentarium.

Naveen Pemmaraju, MD, highlights unmet needs in the setting of myelofibrosis management and looks toward future evolutions in the treatment paradigm.

Expert perspectives on specific subsets of the REFINE study, which combined ruxolitinib with navitoclax in patients diagnosed with myelofibrosis.

Guillermo Garcia-Manero, MD presents a case of lower-risk MDS with chromosome 5q and 20q deletions and a p53 mutation, and discusses first- and second-line treatment selection.

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.

Amer Zeidan, MBBS, and Rami Komrokji, MD, discuss trial updates on oral hypomethylating agents, including data on dosing, for treatment of lower-risk MDS.

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

A biologics license application seeking the approval of remestemcel-L has been resubmitted to the FDA for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

Mitul Gandhi, MD, discusses the rationale of combining brentuximab vedotin, nivolumab, dacarbazine, and doxorubicin for patients with early-stage classic Hodgkin lymphoma, the key findings from part C of the SGN35-027 trial, and the next steps for investigating this combination.

Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of axicabtagene ciloleucel for adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma following at least 2 previous lines of systemic therapy.

The combination of magrolimab, rituximab, gemcitabine, and oxaliplatin produced deep, durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of luspatercept for the treatment of patients with anemia associated with non–transfusion dependent beta thalassemia.

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.